Windtree Therapeutics has not been shy about its desire to become a revenue-generating company, even when achieving that goal ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

BD has become the subject of a lawsuit from Tela Bio, with the rival maker of surgical mesh implants saying the major medtech wielded its sector dominance to push competing products out o | The rival ...

Edwards Lifesciences has claimed an FDA approval for its Sapien M3 transcatheter mitral valve replacement system—marking the ...

Hope is preparing for close-out meetings with the FDA. Chang said the team is “hopeful to advance to a phase 3 confirmatory trial” of the stem cell therapy candidate.

Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic liver disease ...

Big Pharma-backed Aktis Oncology has announced plans to go public, in the latest encouraging sign for those betting on a ...

One of the main threads running through our most-read stories of 2025—as much as ever in the medtech industry writ large—is ...

U.K.-based AstraZeneca has scored the exclusive rights to develop and commercialize the pan-KRAS inhibitor, dubbed JAB-23E73, outside China. On Jacobio’s home territory, the Beijing-headquartered ...

“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.

Boehringer Ingelheim has opened another front in its attack on chronic kidney disease (CKD), offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program.